Research Paper Volume 16, Issue 3 pp 2542—2562
Identification and validation of an H2AZ1-based index model: a novel prognostic tool for hepatocellular carcinoma
Figure 4. Exploring the prognostic efficacy of H2AZ1-based index clinical model in hepatocellular carcinoma. (A) Bar graph showing the expression of H2AZ1-based index in the clinical cohort of patients with hepatocellular carcinoma. (B) Recurrence-free survival (RFS) survival curve of the H2AZ1-based index in TCGA-LIHC data. (C) Overall survival (OS) survival curve of the H2AZ1-based index in TCGA-LIHC data. (D) Survival curves demonstrate the OS prognostic potential of the H2AZ1-based index in the GSE54236 data set. (E) Survival curves demonstrate the OS prognostic potential of the H2AZ1-based index in the GSE14520 data set. (F) Survival curves demonstrate the RFS prognostic potential of the H2AZ1-based index in the GSE76427 data set. (G) Bubble plot showing the correlation between the H2AZ1-based index and clinical indicators. (H) Forest plot showing the univariate prognostic power of the H2AZ1-based index and clinical indicators. (I) Nomogram showing H2AZ1-based index clinical model. (J) Survival curves demonstrating RFS prognostic potential of the H2AZ1-based index clinical model. (K) Survival curves demonstrate the OS prognostic potential of the H2AZ1-based index clinical model. (L) Time-dependent receiver operator characteristic (ROC) curve of the H2AZ1-based index clinical model. (M) Time-dependent ROC curve of TNM stage. (N) Calibration curve demonstrating RFS prognostic potential of H2AZ1-based index clinical model. (O) Calibration curve demonstrating the OS prognostic potential of the H2AZ1-based index clinical model.